Cofactor Genomics Opens $100,000 Predictive Immune Modeling Grant Program for Biomarker Discovery

— Awards Scientists and Clinicians Who Create Predictive Immune
Models and Multidimensional Biomarkers Using the Cofactor ImmunoPrism
Assay —

NEW YORK–(BUSINESS WIRE)–lt;a href=”” target=”_blank”gt;#cofactorlt;/agt;–Cofactor Genomics, pioneers in the field of Predictive Immune Modeling,
announced a $100,000 grant program to reward innovations with the
Cofactor ImmunoPrismTM Assay. The program was unveiled at the
2019 Immuno-Oncology 360° Conference in New York.

In December 2018, Cofactor made
the use of its proprietary database of Health Expression
Models (HEMs). The Health Expression Models leveraged in the ImmunoPrism
Assay enable quantification of immune cells and subtypes in solid tumor
tissue, shown to be important in predicting response to immunotherapies.
Built using machine-learning, these models have been demonstrated to
provide measurable improvements to sensitivity and specificity over
single-gene approaches currently used by the field. Access to Cofactor’s
database of Health Expression Models has empowered translational and
clinical scientists, along with drug development companies to utilize
multidimensional biomarkers in their cancer research and clinical
trials. Early adopters of Cofactor’s Predictive Immune Modeling
technologies include the Fred
Hutchinson Cancer Research Center
, National
Cancer Institute
, and Genocea

“We are sitting on the 10 year anniversary of RNA-seq with shelves
stuffed full of samples and data, created by cell profiling and
analysis, yet we still can’t answer the fundamental question of
predicting which immunotherapy will work with a specific patient or
certain type of cancer,” said Jarret Glasscock, Cofactor CEO and
founder. “The new Predictive Immune Modeling Grant is designed to
inspire the science, research, and clinical communities to take a
different approach to producing highly predictive multidimensional
biomarkers to ultimately solve this massive problem.”

Cofactor Genomics will be showcasing its Predictive Immune Modeling
technology during the Immuno-Oncology 360 conference with a talk in the
“Transactional Science & Emerging Biomarkers” track and the panel on
“Next Generation Biomarker and Companion Diagnostics for Predicting

Applications for the Grant Program will be accepted through April 15,
2019 and more details may be found here:

About Cofactor Genomics

Cofactor Genomics is a Predictive Immune Modeling company. Cofactor has
leveraged its experience as one of the first CAP-certified, clinical RNA
sequencing laboratories to develop new methods that better characterize
disease. Instead of searching for isolated, single-analyte biomarkers,
Cofactor’s products create multidimensional biomarkers that better
capture the complex immune response. Cofactor has pioneered the
molecular and machine learning tools to build Health Expression Models
used for Predictive Immune Modeling. Through their molecular,
informatic, and database tools, Cofactor Genomics enables their partners
to deliver more expedient, cost effective, and successful clinical
trials. Find out more about how Cofactor Genomics is revolutionizing
biomarker discovery and immuno-oncology at


Terri Clevenger
Continuum Health Communications/ICR

error: Content is protected !!